Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163 · clinicaltrials.gov ↗

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure, Systolic

Interventions

DRUG: Sacubitril/Valsartan

Sponsor

Novartis Pharmaceuticals